静脈性下腿潰瘍の世界市場：2023年～2030年

概要

静脈性下腿潰瘍治療（VLU）は、慢性静脈不全（CVI）および静脈性高血圧の後期指標です。正常な状態では、ふくらはぎの筋肉の収縮と腔内弁が血液の逆流を防ぎながら順行性の流れを促進します。しかし、逆行性流、閉塞、またはその両方が存在する場合、結果として生じる慢性静脈高血圧が、VLU形成に至る皮膚および血管合併症の原因となります。

CVIはVLU発症のよく知られた前駆症状であるが、潰瘍形成が起こるのはまれであり（5.1％）、その理由は不明です。CVIは、血液の逆流、閉塞、またはその両方の機序の組み合わせによって発症し、大循環障害および微小循環障害を引き起こします。腔内圧力の上昇は、タンパク質の滲出やフィブリンカフの形成を引き起こし、酸素や成長因子の拡散を阻害し、また炎症反応を活性化します。

市場力学：促進要因と阻害要因

技術的進歩の高まり

治療法の進歩は、予測期間中の静脈性下腿潰瘍治療市場の成長に重要な役割を果たすと予想されます。従来の治療オプションは、多成分や2層の圧迫療法システム、または短期伸張圧迫療法システムへと進化しています。これにより、効果的な治療用圧迫を提供する製品が提供される一方で、臨床医にとっては包帯の装着が容易になり、市場成長の後押しになると期待されています。

例えば、陰圧創傷治療は静脈性下腿潰瘍の治療に用いられる技術の一つです。陰圧創傷治療（NPWT）は、静脈性下腿潰瘍の標準治療を支える技術です。NPWTは、局所浮腫の減少、細菌、炎症性メディエーター、創傷滲出液の減少など、いくつかのメカニズムにより静脈性下腿潰瘍の治癒プロセスを促進します。

また、RMIT大学とボルトンクラーク研究開発の研究者は、慢性創傷をスクリーニングするAIを搭載したツールを開発し、看護師が患者の自宅で最初の評価を行う際に、このような治りにくい創傷を特定できるようにしました。この画期的な技術により、1週間早く傷を発見することが可能となり、オーストラリアの医療システムにとって大きな前進となります。このツールは周囲の温度や光の変化に影響されないため、定期的な家庭訪問や熱帯の環境にも適しています。

さらに、圧迫療法の採用増加、静脈性下腿潰瘍の有病率の上昇など、その他の要因も市場を牽引しており、予測期間中に市場はさらに拡大するものと思われます。

市場力学：阻害要因

治療費の高騰は、市場成長を阻害する主な要因の一つです。例えば、NCBIに掲載された論文によると、米国では静脈性下腿潰瘍の治療費は患者1人当たり年間15,732ドル、英国では7,706ポンドで、英国の人口に換算すると年間20億ポンドを超えます。米国では、人口が多いため治療費が高く、ヘルスケアのインフラが整備されているため費用も高くなります。

さらに、認知度の低さ、償還の制限、高齢化、創傷治療の複雑さ、規制上の課題なども、予測期間中の市場成長を妨げる要因です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 技術の進歩
    • 静脈性下腿潰瘍の有病率の上昇
• 抑制要因
  • 治療に伴う高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• パイプライン分析
• アンメットニーズ
• DMI意見

第6章 COVID-19分析

第7章 治療タイプ別

• 圧迫療法
• 高度創傷被覆材
• デブリードマン
• 薬物療法
• その他

第8章 販売チャネル別

• エンドユーザー
• 流通チャネル

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• 3M
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Integra LifeSciences Corporation
• Smith and Nephew
• Urgo Medical
• Paul Hartmann
• Bauerfeind Canada-Medical.
• Cardinal Health
• Medline
• Essity
• Medi GmbH & Co. KG

第12章 付録

Overview

Venous Leg Ulcers Treatment (VLUs) are late indicators of chronic venous insufficiency (CVI) and venous hypertension. In normal conditions, calf muscle contraction and intraluminal valves promote prograde flow while preventing blood reflux. However, when retrograde flow, obstruction, or both exist, the resultant chronic venous hypertension is responsible for the dermatologic and vascular complications that culminate in the formation of a VLU.

Although CVI is a well-known precipitant for VLU development, ulceration occurs rarely (5.1%) for unclear reasons. CVI may develop due to blood reflux, obstruction, or a combination of both mechanisms, causing macro- and micro-circulatory dysfunction. The increased intraluminal pressure causes protein extravasation and fibrin cuff formation, which impedes the diffusion of oxygen and growth factors, and also activates the inflammatory response.

Market Dynamics: Drivers and Restraints

Rise in technological advancements

Growing advancements in treatment therapy are anticipated to play a vital role in fueling venous leg ulcer treatment market growth during the forecast period. Traditional treatment options have been evolved into multi-component and two-layer compression therapy systems or short-stretch compression therapy systems. This has advanced the ease of bandage application for clinicians while providing them with products that deliver effective therapeutic compression and is expected to boost the market growth.

For instance, negative pressure wound therapy is one of the technologies used in venous leg ulcer treatment. Negative pressure wound therapy (NPWT) is a technology supporting the standard of care in VLUs. NPWT accelerates the healing process of venous leg ulcers with several mechanisms such as local edema reduction, reduction in bacteria, inflammatory mediators, and wound exudate.

Also, researchers at RMIT University and Bolton Clarke Research Institute have developed an AI-powered tool to screen for chronic wounds, enabling nurses to identify these hard-to-heal sores during the first assessment at a person's home. This breakthrough is significant as it allows for the identification of wounds a week earlier, a significant leap forward for the Australian health system. The tool is not sensitive to changes in ambient temperature and light, making it suitable for regular home visits and tropical environments.

Furthermore, the market is also driven by other factors like increasing adoption of compression therapy, rise in the prevalence of venous leg ulcers and others will further drive the market during the forecast period.

Market Dynamics: Restraint

The high cost of treatment is one of the major factors that hamper the market growth. For instance, according to articles published in NCBI in the USA the treatment cost of venous leg ulcers treatment is $15,732 and in the UK s £7,706 per patient per annum, which translates to an annual cost of over £2 billion, when extrapolated to UK population. Comparatively in USA, the treatment cost is higher due to a high number of populations, and improved healthcare infrastructure leads to higher costs.

Furthermore, lack of awareness, limited reimbursement, ageing population, complexity of wound care, regulatory challenges and others are also factors that hamper the market growth rate during the forecast period.

Segment Analysis

The global venous leg ulcers treatment market is segmented based on treatment type, sales channel and region.

The compression therapy segment from the treatment type segment accounted for approximately 41.7% venous leg ulcers treatment market share

The compression therapy segment from the treatment type segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Compression therapy helps increase blood circulation in the lower legs, ankles and feet. It is an effective treatment for pain and swelling caused by conditions associated with poor circulation, such as chronic venous insufficiency and varicose veins. There are many types of compression therapy devices available over the counter or with a prescription.

For instance, in February 2021, Researchers from Tyndall National Institute at UCC; together with researchers from RCSI, University of Medicine and Health Sciences; multinationals DeRoyal Global Healthcare Solutions and Henkel launched a €1 million Enterprise Ireland Innovation Partnership collaboration to innovate the next generation of compression wound care therapy.

Non-healing chronic wounds affect more than 5% of us, with numbers rising due to growing elderly and diabetic populations. These wounds cause significant morbidity and mortality, leading to €12.5 billion in worldwide healthcare costs annually. In some regions of the world, a patient loses a diabetic foot to amputation every 12 seconds.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the novel launches, rise in prevalence of venous leg ulcer cases in the U.S and Canada, rise in R&D for the development of newer products, and favourable reimbursement policies bolster the market.

For instance, in April 2022 Koya Medical stated that it commercially launched its Dayspring active compression system in the U.S. Oakland, California-based Koya designed the wearable Dayspring compression system to treat lymphedema and venous leg diseases in the lower extremities. It features a soft, breathable mesh garment with Koya's proprietary Flexframe - spring-like segments for delivering compression - technology.

Koya said Dayspring for the upper extremity has been commercially available since 2021. Its expansion into lower extremity care (available in both full and lower leg applications) allows the company to better support people with lymphedema and venous diseases.

COVID-19 Impact Analysis

The COVID-19 pandemic has exacerbated the challenge of treating nonhealing vascular ulcers due to lack of multidisciplinary treatment, reduced healthcare resources, and restrictions. This has led to increased morbidity and amputation rates. Training patients in self-care and triage can improve outcomes, even with telemedicine. Governments, scientific committees, and healthcare officials should focus on protecting vulnerable patients during biological storms.

Market Segmentation

By Treatment Type

• Compression Therapy
• Advanced Wound Dressings
• Debridement
• Medications
• Others

By Sales Channel

• End User
  • Hospitals
  • Speciality Clinics
  • Home care Services
  • Others
• Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

major global players in the market include: 3M, Integra Life Sciences Corporation, Smith and Nephew, Urgo Medical, Paul Hartmann, Bauerfeind Canada - Medical., Cardinal Health, Medline, Essity, Medi GmbH & Co. KG and among others.

Key Developments

• In June 2023 JeNaCell, an Evonik company, launched the wound dressing epicite balance onto the German market. Available from June 2023, the dressing is particularly suited and optimized for the treatment of chronic wounds with low to medium exudation, such as venous leg ulcers, arterial leg ulcers, diabetic foot ulcers, pressure ulcers and soft tissue lesions.epicite balance comes in three different sizes and will be distributed through the company Coopmed ApS to hospitals and homecare centres.
• In January 2023, MiMedx Group, Inc. entered into an exclusive distribution agreement with GUNZE MEDICAL LIMITED for the sales of EPIFIX in Japan. EPIFIX is a PURION-processed placental tissue allograft that supports the healing cascade by providing a semi-permeable, protective barrier over wounds.

Why Purchase the Report?

• To visualize the global venous leg ulcers treatment market segmentation based on treatment type, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of venous leg ulcer treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global venous leg ulcers treatment market report would provide approximately 69 tables, 58 figures and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by Sales Channel
• 3.3. Snippet by Region

4. Market Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the technological advancements
    • 4.1.1.2. Rise in the prevalence of venous leg ulcers
• 4.2. Restraints
  • 4.2.1.1. High cost associated with the treatment
  • 4.2.2. Opportunity
  • 4.2.3. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Pipeline Analysis
• 5.6. Unmet Needs
• 5.7. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Compression Therapy *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Advanced Wound Dressings
• 7.4. Debridement
• 7.5. Medications
• 7.6. Others

8. By Sales Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 8.1.2. Market Attractiveness Index, By Sales Channel
• 8.2. End User *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Distribution Channel

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. UK
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.4.1. China
    • 9.5.4.2. India
    • 9.5.4.3. Japan
    • 9.5.4.4. Australia
    • 9.5.4.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. 3M *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Integra LifeSciences Corporation
• 11.3. Smith and Nephew
• 11.4. Urgo Medical
• 11.5. Paul Hartmann
• 11.6. Bauerfeind Canada - Medical.
• 11.7. Cardinal Health
• 11.8. Medline
• 11.9. Essity
• 11.10. Medi GmbH & Co. KG

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us